---
schema_version: "secwatch.filing_event.v1"
accession: "0001714899-22-000021"
form_type: "8-K"
ticker: "DNLI"
cik: "0001714899"
company_name: "Denali Therapeutics Inc."
filed_at: "2022-02-07T23:59:59+00:00"
generated_at: "2026-06-27T10:44:12.640253+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Denali Therapeutics appoints Erik Harris to Board of Directors

## Summary
- Erik Harris appointed to Board and Audit Committee effective Feb 3, 2022, as Class II director.
- Annual cash compensation of $45,000 for Board service, plus $10,000 for Audit Committee.
- Initial equity awards valued at ~$700,000 aggregate (60% option, 40% RSU) with 4-year vesting.
- Harris is Chief Commercial Officer and EVP at Ultragenyx, with 20 years biotech commercial experience.

## SEC filing metadata
- accession: 0001714899-22-000021
- form_type: 8-K
- ticker: DNLI
- cik: 0001714899
- company_name: Denali Therapeutics Inc.
- filed_at: 2022-02-07T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1714899/000171489922000021/0001714899-22-000021-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1714899/000171489922000021/dnli-20220207.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001714899-22-000021
- JSON: https://secwatch.observer/filing/0001714899-22-000021.json
- Plain text: https://secwatch.observer/filing/0001714899-22-000021.txt

## Key facts
- Executive change
  Erik Harris was appointed as Director at Denali Therapeutics Inc..
  - Action: appointed
  - Role: Director
  source text: On February 3, 2022, Erik Harris was appointed to the Board of Directors (the “Board”) and to the Audit Committee of the Board (the "Audit Committee") of Denali Therapeutics Inc. (the “Company”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1714899/000171489922000021/0001714899-22-000021-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.